Genflow Biosciences hails financial position; touts programme progress

(Alliance News) - Genflow Biosciences PLC on Tuesday praised a "resurgence of interest in the longevity sector", positively noting a secure financial position.

The London-based biotechnology company focused on longevity, with research & development facilities in Belgium, said its current cash and grant funding allows for a two-year runway to March 2025. It said it puts it in a more favourable financial position than "many other biotechnology companies".

Meanwhile, it said it continued on its two longevity programmes, with one focused on NASH, a liver disease known as non-alcoholic steatohepatitis. The programme seeks to reverse ageing fibrotic livers to normal functionality. The other programme is focused on Werner syndrome, an accelerated ageing disease for which Genflow aims to improve the life of patients. It added that it will present a detailed application dossier to the Belgian regulatory authorities in early June.

Genflow Biosciences shares were 5.5% higher at 1.74 pence each in London on Tuesday morning.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Genflow Biosci